PUBLIC SUMMARY DOCUMENT

Product: Ezetimibe and Atorvastatin, pack containing 30 tablets ezetimibe 10 mg, and 30 tablets atorvastatin 10 mg (as calcium), atorvastatin 20 mg (as calcium), atorvastatin 40 mg (as calcium) or atorvastatin 80 mg (as calcium), Ezetrol® Plus Atorva

Sponsor: Merck Sharp and Dohme (Australia) Pty Ltd

Date of PBAC Consideration: July 2012

1. Purpose of Application

1) To request an Authority Required (STREAMLINED) listing for the treatment, in conjunction with dietary therapy and exercise, for co-administration of ezetimibe with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who meet certain criteria or who have homozygous familial hypercholesterolaemia.

   The request to list the fixed dose combination product was withdrawn by the sponsor.

2) To Request PBAC advice of exempt item status under subsection 101(4AC) of section 84AH of the National Health Act 1953.

2. Background

The combination pack of ezetimibe with atorvastatin had not been considered previously by the PBAC. However the individual components are available on the Pharmaceutical Benefits Scheme (PBS).

3. Registration Status

Ezetimibe and atorvastatin combination packs were TGA registered on 11 February 2013 for primary hypercholesterolaemia and homozygous familial hypercholesterolaemia. When used in primary hypercholesterolaemia, the composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients, such as those not appropriately controlled with atorvastatin or ezetimibe alone, or, those already treated with atorvastatin and ezetimibe. When used in homozygous familial hypercholesterolaemia, patients may also receive adjunctive treatments (e.g. LDL apheresis).

4. Listing Requested and PBAC’s View

Authority Required (STREAMLINED)

Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have:
(a) coronary heart disease; or
(b) diabetes mellitus; or
(c) peripheral vascular disease; or
(d) heterozygous familial hypercholesterolaemia; or
(e) symptomatic cerebrovascular disease; or
(f) family history of coronary heart disease; or
(g) hypertension.

Inadequate control with a statin is defined as follows:
(1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at the maximum tolerated dose of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or

(2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at the maximum tolerated dose of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated.

Authority Required (STREAMLINED)
Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs).

Prescribing by Medical Practitioners and Nurse Practitioners was requested.

For PBAC’s view, see Recommendation and Reasons.

5. Clinical Place for the Proposed Therapy
The sponsor claimed that the combination of ezetimibe with atorvastatin will replace the individual components being used together for patients whose cholesterol is inadequately controlled with a statin or have homozygous familial hypercholesterolaemia.

6. Comparator
The submission nominated the corresponding doses of the components (ezetimibe and atorvastatin) given concomitantly as the main comparator. The submission also nominated ezetimibe with simvastatin as a secondary comparator. The PBAC considered both comparisons were relevant to a consideration of an ezetimibe with atorvastatin combination pack (co-pack).

7. Clinical Trials
The submission presented one randomised controlled trial (Protocol 0692) comparing the co-administration of ezetimibe and atorvastatin versus the therapies taken individually. The trial enrolled 373 patients with hypercholesterolaemia, however the included patients were not required to be uncontrolled on maximum tolerated doses of statins and patients with coronary heart disease, diabetes mellitus and peripheral vascular disease were excluded from the trial, in contrast to the requested restriction. The primary outcome of the trial was calculated LDL-C reduction (via the Friedewald calculation).

The submission also presented an indirect comparison of the co-administration of ezetimibe
and atorvastatin versus the ezetimibe/simvastatin fixed dose combination (FDC), using placebo as the common reference. This comparison was conducted using data from Protocol 0692 (for the co-administration of ezetimibe and atorvastatin) and Protocol 038 (for the ezetimibe/simvastatin FDC). Protocol 038 enrolled 1,511 patients, however, only patients treated with placebo and the 10/20, 10/40 and 10/80mg ezetimibe/simvastatin FDC doses were considered by the submission (n=605). Like Protocol 0692, Protocol 038 did not require patients to be uncontrolled on maximum tolerated doses of statins and patients with coronary heart disease, diabetes mellitus, peripheral vascular disease and cerebrovascular disease which have become symptomatic were excluded from the trial. Although the baseline characteristics were comparable between the trials, limited information was provided for Protocol 038 to allow for a proper assessment of the comparability of the populations and whether they were sufficiently comparable to inform a meaningful indirect comparison.

The table below details the published trials in the submission.

<table>
<thead>
<tr>
<th>Trial ID/First Author</th>
<th>Protocol title/Publication Title</th>
<th>Publication Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comparison of co-administered ezetimibe and atorvastatin versus the therapies given individually</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cruz Fernandez et al.</td>
<td>Efficacy And Safety Of Ezetimibe Co-Administered With Ongoing Atorvastatin Therapy In Achieving Low-Density Lipoprotein Goal In Patients With Hypercholesterolemia And Coronary Heart Disease.</td>
<td><em>International Journal of Clinical Practice</em> (2005); 59, 6, 619–627</td>
</tr>
<tr>
<td>Blagden et al.</td>
<td>Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease.</td>
<td><em>Current Medical Research and Opinion</em> (2007); 23:767–775</td>
</tr>
<tr>
<td><strong>Indirect comparison of co-administered ezetimibe and atorvastatin versus the ezetimibe/simvastatin FDC (Vytorin®)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ezetimibe + atorvastatin trials Protocol 0692 See above</td>
<td>See above</td>
<td></td>
</tr>
<tr>
<td>Ezetimibe/simvastatin (Vytorin®) trial Protocol 038 Bayes et al.</td>
<td>A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety Profile of the Ezetimibe/Simvastatin Tablet Compared with Ezetimibe and Simvastatin Monotherapy in Patients with Primary Hypercholesterolemia.</td>
<td><em>Clinical Therapeutics</em> (2004); 26:1758-1773</td>
</tr>
</tbody>
</table>

Abbreviations: OL =Open Label, FMI = Final Market Image, FDC = Fixed Dose Combination, R = Randomised, A = Atorvastatin; EZE = Ezetimibe
8. Results of Trials

The results of the comparison of co-administered ezetimibe and atorvastatin versus the therapies taken individually are summarised in the table below (Direct LDL-C, total cholesterol and HDL-C reported in Protocol 0692 from baseline to 12 weeks).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LDL-C</td>
<td>-8.02 (-14.30, -1.74)</td>
<td>-5.51 (-11.87, 0.85)</td>
<td>-2.75 (-9.04, 3.54)</td>
</tr>
<tr>
<td>TC</td>
<td>-6.61 (-11.45, -1.77)</td>
<td>-4.95 (-9.86, -0.04)</td>
<td>-3.22 (-8.11, 1.67)</td>
</tr>
<tr>
<td>HDL-C</td>
<td>-4.82 (-9.46, -0.18)</td>
<td>-4.95 (-9.86, -0.04)</td>
<td>-5.05 (-10.05, -0.05)</td>
</tr>
</tbody>
</table>

E10 = ezetimibe 10mg; A = atorvastatin; E/S = ezetimibe/simvastatin FDC; LDL-C = Low density Lipoprotein Cholesterol; TC = total cholesterol; HDL-C = High Density Lipoprotein Cholesterol

Bolded typography indicates statistically significant differences

The results of Protocol 0692 showed that the co-administration of ezetimibe and atorvastatin provided significant incremental reductions in low density lipoprotein cholesterol (LDL-C)
and total cholesterol and increases in high density lipoprotein cholesterol (HDL-C). The pattern of significant incremental reductions in low density lipoprotein cholesterol (LDL-C) and total cholesterol and increases in high density lipoprotein cholesterol (HDL-C) was also observed in Protocol 038 for the ezetimibe/simvastatin FDC. The use of these trials in an indirect comparison is likely to favour atorvastatin as there are differences in the low density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and high density lipoprotein cholesterol (HDL-C) changes in the placebo arms of both trials, where Protocol 0692 had statistically significant increases in LDL-C, TC and HDL-C, but Protocol 038 had point estimate reductions in LDL-C, TC and HDL-C (none of which are statistically significant). These differences in the placebo arms of the trials may indicate that the patients enrolled in the trials were not sufficiently comparable to inform a meaningful indirect comparison. A comparison of ezetimibe + atorvastatin given concomitantly versus the ezetimibe/simvastatin FDC (comparing combinations corresponding to the dose relativity of 1:2 for atorvastatin: simvastatin) demonstrated that the two are non-inferior - although some statistically significant differences are observed, these are unlikely to be clinically significant as the upper confidence intervals are close to one.

The PBAC considered that the indirect comparison suggested non-inferiority of co-administered ezetimibe + atorvastatin versus the ezetimibe/simvastatin FDC, but the comparison was difficult to interpret, and the results seem to depend on the dose of simvastatin.

Overall, no pattern in the reporting of adverse events was observed to suggest increased risk with co-administration of ezetimibe and atorvastatin versus atorvastatin alone in the subjects examined in Protocol 0692. The PBAC noted that the assessment of risk of harm in study P062 was only over 12 weeks. The extended assessment of harms concluded that the longer term safety profile of atorvastatin + ezetimibe co-pack is expected to be no different to that of the components given concomitantly and generally similar to the profile of atorvastatin given alone.

9. Clinical Claim
The submission described the ezetimibe + atorvastatin co-pack as equivalent in terms of comparative effectiveness and equivalent in terms of comparative safety over the co-administration of ezetimibe and atorvastatin.

For PBAC’s view see Recommendations and Reasons.

10. Economic Analysis
The submission presented a cost-minimisation analysis, which was based on a non-inferiority claim for LDL-C reduction, not including additional costs/offsets for administration or adverse events.

For PBAC’s view, see Recommendations and Reasons.

11. Estimated PBS Usage and Financial Implications
The estimated total net cost to the PBS was less than $10 million in Year 5.

12. Recommendation and Reasons
The PBAC noted that the main comparator nominated in the submission was the corresponding doses of the components (ezetimibe and atorvastatin) given concomitantly, with the ezetimibe/simvastatin fixed dose combination (FDC) as a secondary comparator. The PBAC considered both comparisons were relevant to a consideration of an ezetimibe with atorvastatin combination pack (co-pack).

The PBAC recalled that in 2005 it had recommended simvastatin with ezetimibe (40/10 mg and 80/10 mg) for listing on a cost-minimisation basis compared to the sum of the corresponding strengths (at the price to pharmacist) of the individual components.

The PBAC further recalled that in November 2008, it had advised the Minister under subsection 101(4AC) of the National Health Act 1953 (‘the Act’) that the combination item, a fixed dose tablet containing simvastatin with ezetimibe, provided a significant improvement in compliance, for some patients, over the single agents given concomitantly. In July 2009, at the same time as recommending the listing of two new strengths of the FDC simvastatin with ezetimibe product, 10/10 mg and 10/20 mg, the PBAC extended its subsection 101(4AC) advice to include the new strengths.

The PBAC noted that the current application for a co-pack which includes separate tablets of each component. The Committee considered that the evidence presented in November 2008 and July 2009 was not generalizable to this co-pack presentation. The PBAC also noted that the approach for measuring compliance set out in the Compliance to Medicines Working Group Report to the PBAC had not been addressed, and considered that any future submission seeking PBAC advice to the Minister of a compliance benefit relating to the co-pack should address this approach.

The PBAC was also concerned about the labelling and packaging of the co-pack and the risk that the co-pack may not be used correctly by patients, as patients may take only one tablet each day.

The Committee noted that the proposed price of the ezetimibe and atorvastatin co-pack was higher than that for ezetimibe/simvastatin FDC. The Pre Sub Committee Response argued that this is justified on the basis of the PBAC guidelines for the pricing of fixed dose combinations. However, the PBAC noted that it could only recommend a higher price for the ezetimibe and atorvastatin co-pack if it is satisfied that the co-pack provides, for some patients, a significant improvement in efficacy or reduction of toxicity over the alternative therapy or therapies. The alternative therapies in this case include the ezetimibe with simvastatin FDC. As the indirect comparison of ezetimibe and atorvastatin given concomitantly versus the ezetimibe/simvastatin FDC (at a ratio of 1:2 for atorvastatin: simvastatin as atorvastatin was originally recommended for listing on cost-minimisation basis at this dose relativity) was inadequate to establish superiority of ezetimibe and atorvastatin over the ezetimibe/simvastatin FDC, the PBAC considered a recommendation to list ezetimibe with atorvastatin at a higher price could not be supported.

Lastly, the PBAC considered that the projected number of prescriptions and the financial impact to Government were underestimated by the submission.

Therefore, the PBAC rejected the application to list the ezetimibe with atorvastatin co-pack.
on the PBS because of concerns over the labelling and packaging of the co-pack and because the superiority, in terms of comparative efficacy and safety, over the fixed dose combination ezetimibe with simvastatin has not been demonstrated and that the Committee shall not recommend listing if the proposed drug is substantially more costly than the alternative therapy or therapies unless the PBAC is satisfied that, for some patients, it provides a significant improvement in efficacy or reduction of toxicity over the alternative therapy or therapies.

The PBAC also acknowledged and noted the consumer comments on this item.

**Recommendation:**
Reject

13. **Context for Decision**
The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

14. **Sponsor’s Comment – July 2012**
The sponsor has no comment.

**ADDENDUM**

**PUBLIC SUMMARY DOCUMENT**

**Product:** Ezetimibe and Atorvastatin, pack containing 30 tablets ezetimibe 10 mg, and 30 tablets atorvastatin 10 mg (as calcium), atorvastatin 20 mg (as calcium), atorvastatin 40 mg (as calcium) or atorvastatin 80 mg (as calcium), Atozet Composite Pack® (previously known as Ezetrol Plus Atorva®)

**Sponsor:** Merck Sharp & Dohme (Australia) Pty Ltd

**Date of PBAC Consideration:** November 2012

1. **Purpose of Application**
The minor re-submission sought an Authority Required (Streamlined) listing for the treatment, in conjunction with dietary therapy and exercise, of a patient whose cholesterol levels are inadequately controlled with a statin and who meet certain or who have homozygous familial hypercholesterolaemia.

2. **Summary of Submission**
No new clinical data was presented.

Unlike the previous submission, with respect to Section 101 (4AC) of the *National Health Act*, the current submission stated that the claim of superior compliance compared to alternative therapies was withdrawn.

To address the PBAC’s July 2012 concerns regarding labelling and packaging of the composite packs, the submission stated that all TGA packaging and labelling requirements...
have been met, a Risk Management Plan waiver had been granted and provided reassurance that there is sufficient information provided with the composite packs to ensure that the tablets are taken correctly.

The submission requested pricing on the basis of equivalent pricing to the individual component drugs, ezetimibe and atorvastatin, at the time of listing. The submission further noted and anticipated a future price reduction to atorvastatin.

3. Estimated PBS Usage and Financial Implications
The likely number of packs dispensed per year was estimated in the submission to be greater than 200,000 in Year 5, at an estimated net cost per year to the PBS / Government of less than $10 million in Year 5.

For PBAC’s view, see Recommendation and Reasons.

4. Recommendation and Reasons
The PBAC recalled from its July 2012 meeting that it rejected an application to list the ezetimibe with atorvastatin co-pack on the PBS because of concerns over the labelling and packaging of the co-pack and because the superiority, in terms of comparative efficacy and safety, over the fixed dose combination ezetimibe with simvastatin has not been demonstrated, although, at the time, the price requested for the atorvastatin combination was higher than the price of the simvastatin price. The PBAC also recalled it had not accepted that there was a compliance benefit relating to the co-pack and that both the Economic Sub-Committee and the Drug Utilisation Sub-Committee had expressed concern when considering the July 2012 major submission with regard to the product presentation of two foil strips of the different components in the one pack instead of a fixed dose combination product containing one tablet with both components combined.

The PBAC noted that no new clinical data were presented, and the claim of improved compliance was withdrawn in the new submission, which did however provide a new lower price proposal, and information on measures the sponsor has taken to modify the packaging and labelling of the composite pack.

However, the PBAC was not satisfied that the ezetimibe and atorvastatin composite pack meets the minimum requirements as set out in Part IV of the PBAC Guidelines for combination products. In particular, it is uncertain that the composite pack will not result in unnecessary proliferation of product and/or dose forms and whether there is a clinical need for this composite pack. The PBAC was also concerned, as noted in the Compliance to Medicines Working Group Report (April 2010) that evidence from PBS data suggests a small proportion of consumers who initiate combination products become hyper-compliant due to double dosing from two products containing the same medicines.

The PBAC also noted the submission did not provide any evidence to demonstrate that the measures the sponsor has taken to modify the labelling and packaging of the product to address the quality use of medicines issues identified in the previous submission will be successful.
The PBAC noted also recent data considered by the Drug Utilisation Subcommittee indicating that the market for the component drugs of some combination products did not diminish as expected following listing of the corresponding combination. The PBAC considered this contradictory to the submission’s assumption that listing of the combination product will result in no net cost to the PBS. The PBAC also noted that the combination will be more costly to Government than the alternative therapy of taking corresponding doses of the components (ezetimibe and atorvastatin) concomitantly because of loss of co-payment. As a minor submission, the potential financial impacts of the proposed listing could not be properly quantified or evaluated.

The PBAC therefore rejected the submission on the basis that the co-pack provided no demonstrated clinical or convenience advantage to consumers, the potential increase in cost to Government and the lack of evidence that the composite combination pack would be used appropriately. The PBAC considered in that the issues outstanding would be most appropriately addressed in a major submission.

**Recommendation:**
Reject

5. **Context for Decision**
The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

6. **Sponsor’s Comment – November 2012**
The sponsor did not provide further comment.